Molecular diagnostics of brain tumors using third-generation sequencing

• Conditions: brain tumor; C70; C71; C72; Malignant neoplasm of meninges; Malignant neoplasm of brain; Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system

• Registration Number: DRKS00018102
• Lead Sponsor: Charité Campus Charité Mitte

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-05-21
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 211

Inclusion Criteria

Female or male individuals with planned biopsy or resection of a suspected brain tumor as part of routine clinical procedures, who have given written informed consent.

Exclusion Criteria

None.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
As primary endpoint, we will compare the result of DNA methylation-based classification by nanopore sequencing to match WHO integrated diagnosis as established by routine neuropathological workup.

Secondary Outcome Measures

Name	Time	Method
Additionally, the time interval from receipt of surgical specimens to complete sequencing report (time to diagnosis) will be recorded.